Treat Cancer at Any Stage

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

A Bold, Novel Drug Approach to Kill Tumors and Activate Immune Response to Treat Cancer at Any Stage

Treat locally, act globally. Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.

Tumor
Injection

DfuseRx℠ is our novel proprietary penetration enhancer platform technology that enables therapeutic agents to be injected directly into solid tumors for improved absorption.

Diffusion
Through Tumor

Once injected, DfuseRx enables the injected drug solution to disperse throughout the tumor and increases the drug’s diffusion into cancer cells.

Localized
Cell Death

The absorbed active agents in the injected tumor induce cancer cell death, without disruption of the cell membrane, in a manner that results in an influx of immune cells throughout the tumor.

System-wide
Immune Response

Tumor cell death exposes the immune system to antigens of the patient’s own cancer, inducing a personalized CD4+ and CD8+ T cell response, attacking the site of the former tumor while attacking distal cancer sites.

Increased
Survival

Exploratory analysis of data from a Phase 1/2 trial of relapsed and refractory solid tumor patients with a variety of cancers indicates an association between percent of tumor burden treated and survival.

Technology and Clinical Data

DfuseRxSM is our novel proprietary product discovery technology that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption. The technology makes use of novel dispersion and cell penetration enhancer molecules that we have identified.
Play Video

Register for News Updates:

Subscribe to our company news email list and receive news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.

Latest Tweets:

These strongly encouraging results in our two @ASCO presentations provide further support of INT230-6’s potential in directly killing tumors and shrinking them through abscopal effects.

#ASCO21

Use of INT230-6 alone or in combination with ipilimumab showed a median overall survival of 23.6 months in advanced sarcoma/chordoma patients compared to an expected survival of only 4 to 8 months for these patients in phase 1/2 studies.

#ASCO21

Major @ASCO data highlights include an estimated 62% one-year survival for INT230-6 monotherapy subjects and 88% one-year survival when combined with pembrolizumab.

#ASCO21

We’re presenting 2 posters showcasing data that demonstrates INT230-6’s efficacy/tolerability in patients with solid tumors, as a monotherapy and in combination with checkpoint inhibitors, at the 2021 @ASCO Annual Meeting (June 4-8).

Details here: https://bit.ly/3yW8G0c
#ASCO21

Our first #ASCO 2021 presentation describes results in patients receiving INT230-6 alone or with pembrolizumab. The second presentation is of INT230-6 in advanced #sarcoma alone and with ipilimumab.

Load More...